Humaid Al-Shamsi, The Chairman of Nexomic, shared on LinkedIn:
“Precision oncology is changing how we detect resistance, personalize treatment, and bring the latest advances in cancer care closer to patients In the latest edition of Burjeel Proud newsletter, I shared insights on Burjeel Cancer Institute’s global milestone in administering Etcamah (camizestrant), a next-generation oral targeted therapy for advanced breast cancer.
It was a pleasure to discuss how this milestone was achieved, the role of molecular diagnostics and precision oncology, and what it means for patients in the UAE to access advanced cancer care closer to home.
Other articles featuring Humaid Al-Shamsi on OncoDaily.
